Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03283137
Recruitment Status : Recruiting
First Posted : September 14, 2017
Last Update Posted : April 17, 2018
Sponsor:
Information provided by (Responsible Party):
University of Chicago

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2020
  Estimated Study Completion Date : December 2020